Published in Curr Opin Oncol on September 01, 2004
Surgical pathology in sub-Saharan Africa--volunteering in Malawi. Virchows Arch (2012) 1.46
Lymphomas in sub-Saharan Africa--what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research? Br J Haematol (2011) 1.39
Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology (2007) 1.38
The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One (2010) 1.34
Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol (2007) 1.32
Intraepithelial and invasive squamous neoplasms of the conjunctiva in Ibadan, Nigeria: a clinicopathological study of 46 cases. Int Ophthalmol (2008) 1.00
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol (2009) 0.92
AIDS-Related Non-Hodgkin's Lymphoma in Sub-Saharan Africa: Current Status and Realities of Therapeutic Approach. Lymphoma (2012) 0.91
HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma. PLoS One (2010) 0.87
Factors associated with colposcopy-histopathology confirmed cervical intraepithelial neoplasia among HIV-infected women from Rio De Janeiro, Brazil. PLoS One (2011) 0.87
Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings. Adv Hematol (2012) 0.86
Epidemiology and management of ocular surface squamous neoplasia in Tanzania. Ophthalmic Epidemiol (2010) 0.83
HHV-8 seroprevalence: a global view. Syst Rev (2014) 0.81
Harnessing information and communication technologies to leverage scarce resources for cancer education, research and practice in developing countries. Health Res Policy Syst (2006) 0.77
Co-infections and Pathogenesis of KSHV-Associated Malignancies. Front Microbiol (2016) 0.76
Serum prostate-specific antigen levels in older men with or at risk of HIV infection. HIV Med (2006) 0.75
Risk factors for common cancers among patients at Kamuzu Central Hospital in Lilongwe, Malawi: A retrospective cohort study. Malawi Med J (2017) 0.75
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. J Clin Oncol (2013) 2.07
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res (2002) 2.05
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res (2004) 1.91
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.87
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol (2003) 1.79
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.69
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res (2005) 1.66
Multi-institutional phase I trials of anticancer agents. J Clin Oncol (2008) 1.65
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol (2007) 1.56
Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol (2011) 1.54
Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res (2008) 1.49
A medical oncologist's approach to immunotherapy for advanced renal tumors: is nephrectomy indicated? Curr Urol Rep (2004) 1.39
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol (2010) 1.38
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid (2009) 1.35
Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol (2006) 1.21
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid (2013) 1.19
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2007) 1.15
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood (2013) 1.13
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol (2003) 1.12
Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery. Nat Clin Pract Oncol (2006) 1.12
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res (2009) 1.10
Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. Clin Cancer Res (2003) 1.09
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am J Hematol (2009) 1.09
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid (2013) 1.07
Ocular surface squamous neoplasia in patients with HIV infection in sub-Saharan Africa. Curr Opin Oncol (2010) 1.06
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.04
Barriers to recruitment of rural patients in cancer clinical trials. J Oncol Pract (2011) 1.01
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res (2007) 0.99
Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr Oncol Rep (2005) 0.98
Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys (2009) 0.97
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol (2004) 0.97
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol (2011) 0.96
Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol (2007) 0.95
Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa. J Natl Cancer Inst (2002) 0.94
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res (2007) 0.94
Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol (2010) 0.93
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol (2009) 0.92
Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncol Rep (2011) 0.91
AIDS-Related Non-Hodgkin's Lymphoma in Sub-Saharan Africa: Current Status and Realities of Therapeutic Approach. Lymphoma (2012) 0.91
Phase I trial of pomalidomide given for patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.90
HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma. PLoS One (2010) 0.87
Preliminary clinical and pharmacologic investigation of photodynamic therapy with the silicon phthalocyanine photosensitizer pc 4 for primary or metastatic cutaneous cancers. Front Oncol (2011) 0.87
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer Chemother Pharmacol (2009) 0.87
Capacity building for the clinical investigation of AIDS malignancy in East Africa. Cancer Detect Prev (2005) 0.87
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol (2009) 0.84
Declining mammography screening in a state Medicaid Fee-for-Service program: 1999-2008. J Womens Health (Larchmt) (2012) 0.84
Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Curr Opin Oncol (2006) 0.84
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs (2008) 0.84
Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program. J Womens Health (Larchmt) (2011) 0.84
The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting. Heart Fail Clin (2011) 0.84
Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study. PLoS One (2011) 0.84
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematol Oncol (2011) 0.83
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs (2008) 0.83
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J (2012) 0.83
Bendamustine-associated hemolytic anemia. Ann Pharmacother (2009) 0.80
Novel agents for the treatment of advanced kidney cancer. Clin Adv Hematol Oncol (2004) 0.80
Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies. Clin Exp Metastasis (2013) 0.80
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. Invest New Drugs (2009) 0.80
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemother Pharmacol (2011) 0.79
Model-free parameters from dynamic contrast-enhanced-MRI: sensitivity to EES volume fraction and bolus timing. J Magn Reson Imaging (2006) 0.79
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. Semin Oncol (2003) 0.79
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol (2008) 0.78
Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. Invest New Drugs (2005) 0.77
Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. Arch Dermatol (2012) 0.77
Promising systemic therapy for renal cell carcinoma. Curr Treat Options Oncol (2005) 0.76
Myocardial stunning following combined modality combretastatin-based chemotherapy: two case reports and review of the literature. Clin Cardiol (2009) 0.76
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol (2008) 0.75
The evolving role of statins in hematopoietic stem and progenitor cell transplantation. Am J Blood Res (2011) 0.75
Surrogate markers in oncology practice and anticancer drug development: lessons learned from antiretroviral therapy? Cancer Invest (2004) 0.75
Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies. Anticancer Res (2014) 0.75
Building a statewide clinical trials network for cancer care in West Virginia. W V Med J (2009) 0.75
Bonnie's Bus--cancer disparities in West Virginia, philanthropy and opportunities to build lasting partnerships. W V Med J (2009) 0.75